Oslo, Norway, 23rd of August 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2024. Revenue in the second quarter ended at MNOK 106 compared to MNOK...
Saga Pure ASA has on 23 August 2024 purchased 300,000 shares in Vistin Pharma ASA at NOK 22,50 per share. After the transaction Saga Pure ASA has a holding of 400,000 shares, corresponding to 0.9 %...
The shares in Vistin Pharma ASA will be traded ex dividend NOK 0.50 as from today, 05.06.2024. ...
Oslo, Norway, 23 May 2024 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 23th of May, the Company's Chair of the Board, ˜yvin Br¸ymer, has received open...
Oslo, Norway, 23 May 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 23 May 2024. All matters were resolved as proposed in...
Oslo, Norway, 30 April 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 23 May 2024 at 13:00 CEST. A physical...
Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to...
Oslo, Norway, 24 April 2024 Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full...
Oslo, Norway, 16 April 2024 Vistin Pharma ASA will release its first quarter results on Wednesday 24th of April 2024. Vistin Pharma will host a conference call for all shareholders and interested...
Pactum Vekst AS has on March 22, 2024 sold 527 960 shares in Vistin Pharma ASA at a price of NOK 22,10 per share. Espen W. Marcussen, Chair of the board in Pactum Vekst AS, is a primary insider and...